Lupus Nephritis
Conditions
Interventions
Standard treatment group:None
Lupus nephritis (LN) patients treated with telitacicept:None
Sponsors
Affiliated Hospital of Guangdong Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Patients aged between 18 and 65 years who meet the diagnostic criteria for LN and present with persistent hypocomplementemia; 2.Patients receiving either standard lupus therapy or Telitacicept combined with standard therapy (glucocorticoids and/or antimalarials and/or immunosuppressants including cyclophosphamide, mycophenolate mofetil, tacrolimus, cyclosporine, etc.).
Exclusion criteria
Exclusion criteria: 1. Patients with a history of treatment with any biological agents other than Telitacicept; 2. Patients with severe organic lesions in important organs such as the liver, spleen, or lungs; 3. Patients with primary hematopoietic system diseases; 4. Patients with rheumatoid arthritis, viral hepatitis, or other immune system diseases; 5. Female patients who are breastfeeding or pregnant; 6. Patients with missing clinical data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum complement C3 and C4 levels; | — |
Secondary
| Measure | Time frame |
|---|---|
| Covering multiple disease-related indicators: including the degree of reduction in SLEDAI score, reduction in urinary protein quantification, improvement in renal function indicators (such as serum creatinine and estimated glomerular filtration rate), and incidence of adverse events.; | — |
Countries
China
Contacts
Public ContactYao Cuiwei
Affiliated Hospital of Guangdong Medical University
Outcome results
None listed